nextHERIZON
04 May 2022
Trial Summary
An Open-Label, Signal Generating, Phase 2 Study Of Her-Vaxx In Combination With Chemotherapy Or Pembrolizumab In Patients With Metastatic Her2/Neu Over-Expressing Gastric Or Gastroesophageal Junction (Gej) Adenocarcinomas Who Have Previously Received Trastuzumab And Progressed On This Treatment
Acronym:
nextHERIZON
ACTRN/NCT /ethics:
NCT05311176
Scientific title:
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
Sponsor / Cooperative group:
Imugene Limited
Trial & Patient Characteristics
| Cancer Type | Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2022-05-17 |
| Anticipated End Date | 2025-11-01 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Stella Papacharissiou |
| stella.papacharissiou@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Timothy Price |
| Recruitment Status | Recruiting |